Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Women's Health - Endometriosis Drug Pipeline Report' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Women's Health Therapeutics Market to 2017 High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market |
Jan 2012 | £2,215 | 88% |
| Endometriosis Pipeline Assessment and Market Forecasts to 2017 |
Dec 2010 | £1,265 | 86% |
| Stakeholder Opinions: Endometriosis Scientific Clarity Will Unlock Market Potential |
Dec 2007 | £2,400 | 79% |
| Women's Health: Worldwide Prescription Drug Markets, 4th Edition | Feb 2009 | £1,895 | 76% |
| The World Market for Gynaecology 2007-2017 |
Sep 2007 | £3,200 | 73% |
| Pharmaceutical Industry - 2010 Yearbook Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions |
Dec 2010 | £2,215 | 72% |
| Worldwide Prescription Drug Market for Womens Health Now and Future 2004-2009 |
Feb 2005 | £1,135 | 69% |
| Women's Reproductive Disorders Therapeutics 2008-2018 | Sep 2008 | £1,499 | 69% |
| Stakeholder Insight: Infertility Undifferentiated drugs force need to strengthen prescriber and payer relationship |
Dec 2008 | £8,365 | 53% |
- Results 1 - 9 of 9
-
-
- 1
-
-
